TABLE 3.
COVID‐related autoimmune diseases treated with IVIg. In pemphigus vulgaris 111 and myasthenia gravis exacerbation, 112 IVIg was preferred to other first‐line immunosuppressive therapies in order not to increase the infectious risk
| Disease (Ref.) | Treatment and dose |
|---|---|
| Guillain‐Barré syndrome 91 , 92 , 93 | IVIg 0.4 g/kg/day for 5 days |
| Kawasaki disease 91 , 93 | IVIg 2 g/kg single dose +aspirine |
| Multisystem Inflammatory Syndrome in Children (MIS‐C) 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 | IVIg 2 g/kg single or double dose +high‐dose steroid +aspirine |
| Evans syndrome 111 | IVIg 1 g/kg/day +high‐dose steroids +plasmapheresis |
| Pemphigus vulgaris 112 | IVIg only as first line or associated with high‐dose steroid |
| Myasthenia gravis exacerbation 113 | IVIg 2 g/kg in 5 days as first line |
| Immune thrombocytopenic purpura 114 | IVIg 1 g/kg +high‐dose steroid as first line |
| Acute disseminated encephalomyelitis (ADEM) 115 | IVIg 2 g/kg in 5 days +high‐dose steroid |